Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.0737
Abstract: Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma To the Editor Siu and colleagues1 conducted the largest clinical trial to date to… read more here.
Keywords: plus panitumumab; radiotherapy; afx plus; plus cisplatin ... See more keywords
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-000403
Abstract: Background FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed… read more here.
Keywords: metastatic colorectal; braf wild; colorectal cancer; plus panitumumab ... See more keywords